Latest Strategic Partnership News

PLS Group reported a robust first half of FY26, with lithium production up 6% and a 40% jump in realised prices driving a 47% revenue increase. Underlying EBITDA soared 241%, underscoring operational efficiency and cost discipline.

Rhythm Biosciences reported a $2.26 million half-year loss as it advances ColoSTAT into commercialisation and expands geneType partnerships, signalling a pivotal phase for the ASX-listed medical diagnostics company.

Knosys Limited reported a 4.6% revenue increase to $5.07 million for the half-year ending December 2025, driven by stronger licence and project fees. However, the company’s net loss widened significantly to $1.53 million, reflecting heavy investment in its next-generation Libero X library management system.

Cleo Diagnostics has chosen Bio-Techne’s next-generation Ella™ platform to enhance its ovarian cancer blood test, aiming for faster, more precise results and a streamlined path to FDA approval.

EV Resources has successfully produced its first metallic antimony ingots from the Los Lirios project in Mexico, validating a low-cost smelting process and advancing its strategy to supply the North American market.

Star Minerals has entered a strategic partnership with Catalyst Metals, securing a gold milling agreement for its Tumblegum South project and selling its West Bryah Basin copper-gold assets for $2.75 million. Catalyst also commits to a $1 million equity placement in Star Minerals, underpinning the company’s development plans.

Magellan Financial Group has reported a 5% rise in operating earnings per share and a striking 50% increase in its fully franked interim dividend, underpinned by strong contributions from strategic partnerships and disciplined capital management.

Magellan Financial Group reported a 27% drop in statutory net profit but maintained stable operating profit and increased earnings per share by 5%, supported by ongoing share buybacks. The company declared a fully franked interim dividend up 50%, reflecting confidence despite investment performance challenges.

Starpharma reports a $1.37 million profit for H1 FY26, driven by a major upfront payment from Genentech and progress in its radiopharmaceutical pipeline. The biotech also expands its consumer health footprint amid growing partnerships.

Hansen Technologies has reported a remarkable half-year performance with a 7.3% revenue increase and a staggering 31,000% rise in statutory net profit, underpinned by a strategic acquisition of the Digitalk Group.

Netwealth Group Limited has reported a robust first half of FY26, with record funds under administration and a significant increase in dividends, underpinned by strong inflows and strategic technology investments.

BCAL Diagnostics reported a slight revenue decline and a persistent net loss in its half-year results, with auditors flagging concerns over its ability to continue without additional funding.